Anzeige
Mehr »
Login
Dienstag, 01.10.2024 Börsentäglich über 12.000 News von 692 internationalen Medien
Goldpreis steigt 2024 um 30 %, aber diese Aktie legt über 333 % zu – Hier ist der Grund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
301 Leser
Artikel bewerten:
(1)

MarketFinance Becomes CBILS Lender to Speed up Finance to UK Businesses

- Lending: MarketFinance approved for accreditation as a new lender under Coronavirus Business Interruption Loan Scheme (CBILS) by the British Business Bank

- Products: Businesses will be able to apply for loans and invoice finance products, both accredited under CBILS

- X-factor: Advanced, tech-based risk model to process online applications quickly and provide faster decisions to businesses; getting more money to businesses in need

- SMEs: Open to all eligible businesses with a minimum turnover of £100k

LONDON, May 14, 2020 /PRNewswire/ -- Fintech business lender MarketFinance has today been accredited by the British Business Bank as a lender under the government-backed Coronavirus Business Interruption Loan Scheme (CBILS).

The Coronavirus Business Interruption Loan Scheme is designed to support the continued provision of finance to UK smaller businesses (SMEs) during the Covid-19 outbreak. The scheme enables lenders to provide facilities of up to £5m to smaller businesses across the UK who are experiencing lost or deferred revenues, leading to disruptions to their cashflow.

From today, businesses can immediately express their interest for a CBILS loan or invoice finance facility through MarketFinance via its website here. MarketFinance will be able to receive and process CBILS applications in the coming days.

Minimum eligibility criteria for business loans and invoice finance through MarketFinance:

  • Limited Company or Limited Liability Partnership
  • Trading for more than 24 months, has a turnover of more than £100k
  • Company sells goods and services to consumer and other businesses

Anil Stocker, CEO at MarketFinance, commented: "Businesses are looking to trade their way out of this crisis and CBILS allows them to unlock funding they might not have found otherwise. Here at MarketFinance, our technology and risk underwriting platform is at the heart of what we do. We've been processing large volumes of applications and delivering rapid funding decisions since we launched in 2011, and we're going to use this foundation to get as much funding out to businesses in this crucial time.

"Fintech was born out of the last financial crisis of 2008, and I'm proud that MarketFinance is now one of the platforms playing such a crucial role in channelling funds to UK businesses."

Business Loans

Under the CBILS, the first 12 months of interest on the loan and any arrangement fees will be paid by the UK Government as a Business Interruption Payment. This means smaller businesses will benefit from no upfront costs and lower initial repayments. No personal guarantees will be required, so borrowers and guarantors will not have to put up their principal private residence as security. SMEs can apply for a MarketFinance CBILS term loan (up to 3 years) between £50,001 and £150,000.

Invoice Finance

Businesses looking for cash flow or working capital can get finance on their outstanding invoices (with long payment terms, where they are waiting to be paid on work completed). As with business loans, there will be no arrangement fees or interest charged. SMEs with an annual turnover of up to £45 million can apply for a MarketFinance CBILS invoice finance facility (for up to 3 years) between £50,001 and £5m.

Notes to the Editor

The Coronavirus Business Interruption Loan Scheme (CBILS) is managed by the British Business Bank on behalf of, and with the financial backing of the Secretary of State for Business, Energy and industrial Strategy (BEIS).

For further information please contact: MarketFinance press office: Bilal Mahmood on b.mahmood@marketfinance.com or +44-(0)20-3640-7759 and +44-(0)771-400-7257.

About MarketFinance

MarketFinance is a business finance company with offices in London and Manchester. The online platform enables businesses to access a range of flexible finance solutions - quickly and easily. This smart technology is backed by help from real people so business owners can save time and focus on growing their business.

Since 2011, MarketFinance has advanced over £2.9 billion to companies across a range of sizes and sectors, providing working capital and finance for everything from paying staff and suppliers to launching new products or services and accelerating growth.

MarketFinance is backed by Barclays, Santander InnoVentures, European venture capital fund Northzone (invested in Klarna, iZettle and Trustpilot), private equity group MCI Capital (also invested in iZettle, Azimo and Gett) and Viola Credit.

Further information visit: www.marketfinance.com or follow us on LinkedIn and Twitter.

© 2020 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.